Roche signs $1.16B obesity drug deal with China’s Rona Therapeutics

What happened: Roche (RHHBY) signed an exclusive worldwide licensing deal with China's Rona Therapeutics for an experimental obesity drug candidate. Key numbers: Deal worth up to $1.16B. $100M upfront, up to $1.06B in milestones, plus tiered royalties on global net sales. Why it matters: The RNAi therapy targets ALK7 and may preserve lean mass, potentially complementing existing incretin-based obesity drugs. The deal strengthens Roche's obesity pipeline as it competes with Eli Lilly (LLY) and Novo Nordisk (NVO). Market: +3.7% by next close ($1,210.72 on Oct 14), +12.4% YTD

Roche (RHHBY) signed an exclusive worldwide licensing deal with China's Rona Therapeutics for an experimental obesity drug candidate.

The RNAi therapy targets ALK7 and may preserve lean mass, potentially complementing existing incretin-based obesity drugs. The deal strengthens Roche's obesity pipeline as it competes with Eli Lilly (LLY) and Novo Nordisk (NVO). Market: +3.7% by next close ($1,210.72 on Oct 14), +12.4% YTD